Large-scale randomized controlled trials, including the SUSTAIN and STEP trial programs involving thousands of participants, have not identified immunosuppression as an adverse effect of semaglutide therapy
*Correspondence: Roberta Poli, [email protected] These authors have contributed equally to this work and share first authorship This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Learn more about tirzepatide here
The bear case is, for any variety of reasons, be it health risk, lack of efficacy, or whatever
Cities served include: Eligible patients may qualify for telehealth consultations and ongoing provider-supervised GLP-1 treatment from home
Based on the study data available so far, the key difference lies in efficacy